Aripiprazole is an atypical antipsychotic, second generation, indicated for schizophrenia and other psychoses, is an atypical antipsychotic drug approved by the FDA. The aripiprazole is an antipsychotic drug that works by changing the actions of chemicals in the brain. It is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder, or with other medicines to treat major depressive disorder in adults. “Aripiprazole is also used to treat symptoms of irritability and aggression, mood swings and self-injury related to autism”.( Lynn Marks(2015).
The active ingredient aripiprazole belongs to a group of medicines called antipsychotics. It is used to treat adults who suffer from a disease characterized by symptoms such as hearing, seeing and feeling things that are not there, suspiciousness, mistaken beliefs, incoherent speech and behavior and emotional monotony. People in this state may also feel depressed, guilty, anxious or tense. The atypical antipsychotic agent aripiprazole reduces symptoms of irritability in children and adolescents with autism, but, although it is generally well tolerated, its use is associated with a higher dropout rate due to adverse effects and weight gain. This neuroleptic can be administered orally, sublingually, intramuscularly or intravenously as appropriate and via commercial product. Upon reaching the brain occupy neurotransmitter receptors known as dopamine and in some cases also serotonin. They act as antagonists by blocking their effects and produce a state of tranquility and immediate indifference. History Aripiprazole is sometimes referred to as a third-generation antipsychotic to denote a difference from other available atypical (second-generation) antipsychotics. Produced by Otsuka Pharmaceutical Co. Japan. It approved by the FDA for the treatment schizophrenia is atypical antipsychotic sixth achieved this status. In 1972 Professor Arvid Carlsson proposed the existence of presynaptic dopamine autoreceptors that negatively regulate dopamine synthesis, release and firing of dopaminergic neurons. Based on the dopamine hyperactive theory of schizophrenia. The Food and Drug Administration (FDA) approved in 2002 the indication of aripiprazole for the treatment of schizophrenia in adults and adolescents aged 13 to 17 years. Subsequently, the FDA included two new indications: maintenance treatment of patients with bipolar disorder with recent episode of mania or mixed in adults and children aged 10 to 17, and adjunctive treatment of major depression in adults. Recently the same agency approved indications in the treatment of irritability in autism in children and adolescents between 6 and 17 years. Aripiprazole is the first FDA partial agonist showing therapeutic efficacy as an antipsychotic, approved by regulatory agencies for clinical use. The development and adoption constitute an event in the historical development of antipsychotics, innovation in the therapeutic arsenal. Innovation in the mechanism of action of antipsychotic Composition Specialty pharmaceutical composition of aripiprazole. 5 mg, 10 mg, 15 mg ABILIFY tablets It includes aluminum lake indigo carmine, Lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, dyes, calcium silicate, croscarmellose sodium, crospovidone, silica, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, flavorings, tartaric acid , magnesium stearate.( Abilify/vita-health.weebly.com) Aripiprazole is a drug belonging to a class of drugs called atypical antipsychotics. …show more content…
Its mechanism of action is to modify the activity of natural substances in the brain, and is used to treat the symptoms of schizophrenia, a psychotic disorder that is characterized as a disturbance that lasts at least 6 months and includes at least 1 month symptoms of the active phase, as they are for example: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior and negative symptoms called. There are two types of drugs, typical and atypical, both tend to block the ladopaminic receptor pathway in the brain. Some side effects include weight gain, agranulocytosis, dyskinesia and tardive akathisia. The aripiprazole is an atypical antipsychotics. Atypical antipsychotics are a heterogeneous group of unrelated, except for the fact that its mechanism of action differs from typical antipsychotic drugs. Many have the common power to act on serotonin receptors and dopamine receptors. The average life of aripiprazole are approximately 75 hours and the active metabolite of 94 hours. The steady state is reached, rough-mind, within 14 days of starting treatment. The dose is 15 to 30 mg. per day in one or two takes. No dose adjustments should be made in the kidney or liver failure, elderly or smokers. Side effects that may occur, but have low incidence, are: anxiety, distal tremor, orthostatic hypotension
The active ingredient aripiprazole belongs to a group of medicines called antipsychotics. It is used to treat adults who suffer from a disease characterized by symptoms such as hearing, seeing and feeling things that are not there, suspiciousness, mistaken beliefs, incoherent speech and behavior and emotional monotony. People in this state may also feel depressed, guilty, anxious or tense. The atypical antipsychotic agent aripiprazole reduces symptoms of irritability in children and adolescents with autism, but, although it is generally well tolerated, its use is associated with a higher dropout rate due to adverse effects and weight gain. This neuroleptic can be administered orally, sublingually, intramuscularly or intravenously as appropriate and via commercial product. Upon reaching the brain occupy neurotransmitter receptors known as dopamine and in some cases also serotonin. They act as antagonists by blocking their effects and produce a state of tranquility and immediate indifference. History Aripiprazole is sometimes referred to as a third-generation antipsychotic to denote a difference from other available atypical (second-generation) antipsychotics. Produced by Otsuka Pharmaceutical Co. Japan. It approved by the FDA for the treatment schizophrenia is atypical antipsychotic sixth achieved this status. In 1972 Professor Arvid Carlsson proposed the existence of presynaptic dopamine autoreceptors that negatively regulate dopamine synthesis, release and firing of dopaminergic neurons. Based on the dopamine hyperactive theory of schizophrenia. The Food and Drug Administration (FDA) approved in 2002 the indication of aripiprazole for the treatment of schizophrenia in adults and adolescents aged 13 to 17 years. Subsequently, the FDA included two new indications: maintenance treatment of patients with bipolar disorder with recent episode of mania or mixed in adults and children aged 10 to 17, and adjunctive treatment of major depression in adults. Recently the same agency approved indications in the treatment of irritability in autism in children and adolescents between 6 and 17 years. Aripiprazole is the first FDA partial agonist showing therapeutic efficacy as an antipsychotic, approved by regulatory agencies for clinical use. The development and adoption constitute an event in the historical development of antipsychotics, innovation in the therapeutic arsenal. Innovation in the mechanism of action of antipsychotic Composition Specialty pharmaceutical composition of aripiprazole. 5 mg, 10 mg, 15 mg ABILIFY tablets It includes aluminum lake indigo carmine, Lactose monohydrate, corn starch, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, dyes, calcium silicate, croscarmellose sodium, crospovidone, silica, xylitol, microcrystalline cellulose, aspartame, acesulfame potassium, flavorings, tartaric acid , magnesium stearate.( Abilify/vita-health.weebly.com) Aripiprazole is a drug belonging to a class of drugs called atypical antipsychotics. …show more content…
Its mechanism of action is to modify the activity of natural substances in the brain, and is used to treat the symptoms of schizophrenia, a psychotic disorder that is characterized as a disturbance that lasts at least 6 months and includes at least 1 month symptoms of the active phase, as they are for example: delusions, hallucinations, disorganized speech, grossly disorganized or catatonic behavior and negative symptoms called. There are two types of drugs, typical and atypical, both tend to block the ladopaminic receptor pathway in the brain. Some side effects include weight gain, agranulocytosis, dyskinesia and tardive akathisia. The aripiprazole is an atypical antipsychotics. Atypical antipsychotics are a heterogeneous group of unrelated, except for the fact that its mechanism of action differs from typical antipsychotic drugs. Many have the common power to act on serotonin receptors and dopamine receptors. The average life of aripiprazole are approximately 75 hours and the active metabolite of 94 hours. The steady state is reached, rough-mind, within 14 days of starting treatment. The dose is 15 to 30 mg. per day in one or two takes. No dose adjustments should be made in the kidney or liver failure, elderly or smokers. Side effects that may occur, but have low incidence, are: anxiety, distal tremor, orthostatic hypotension